

**Project Title:** 



"RT-QuIC assay on olfactory brushings in asymptomatic carriers of E200K PRNP mutation: an explorative study for establishing when a preventative therapy should be started "

### Gianluigi Zanusso

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona

### **Genetic Prion Diseases**

 Human PrP gene (PRNP) mutations correlate to distinct disease phenotypes such as: Genetic Creutzfeldt-Jakob Disease (gCJD)
Fatal Familial Insomnia Gerstmann Straussler Scheincker syndrome PrP systemic amyloidosis

The disease phenotype of gCJD is characterized by a rapidly progressive neurological disorder

- Mutation carriers of E200K develop a gCJD. E200K is diffuse worldwide with clusters in Slovakia, Italy (Calabria region), and among Libyan Jews in Israel
- For unknown reasons, the penetrance of E200K mutation varies among clusters and the probability to develop CJD in Calabrians is 50% at the age of 60 and 61% at the age of 70 (D' Alessandro M. et al. Lancet 1998)

### **Prion Conversion and Replication in Genetic Prion Diseases**



# **Pre-clinical Diagnosis of Prion Disease ?**



### Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and <sup>18</sup>FDG-PET studies

Pietro Cortelli,<sup>3</sup> Daniela Perani,<sup>1</sup> Pasquale Montagna,<sup>3</sup> Roberto Gallassi,<sup>3</sup> Paolo Tinuper,<sup>3</sup> Provini Federica,<sup>3</sup> Patrizia Avoni,<sup>3</sup> Franco Ferrillo,<sup>4</sup> Davide Anchisi,<sup>1</sup> Rosa Maria Moresco,<sup>2</sup> Ferruccio Fazio,<sup>2</sup> Piero Parchi,<sup>3</sup> Agostino Baruzzi,<sup>3</sup> Elio Lugaresi<sup>3</sup> and Pierluigi Gambetti<sup>5</sup>

#### [18F]FDG PET longitudinal studies of subject 6



13 months before clinical onset



7 months after clinical onset



### **Prion Conversion and replication in Genetic Prion Diseases**



### **RT-QuIC Assay and Olfactory Brushing**



# Short movie of Nasal Brushing Procedure

## Diagnostic Accuracy of OM brushing coupled with RT-QuIC

**Olfactory Mucosa brushing is:** 

- > Easily performed: It does not require trained otolaryngologists
- Non-invasive: No medical or surgical complications or a smell disorder
- Highly efficient: It collects around 300.000 olfactory neurons with a single sampling
- Highly sensitive: RT-QuIC assay of OM detects pathological PrP seeding activity in OM of CJD patients with a 97% sensitivity and 100% specificity

RT-QuIC assay in Olfactory Brushingsof patients with sporadic CJD and E200K using Hamster PrP 23-231 at 42°C



# Migration of E200K family members from rural region of Calabria to the Northern Italy

E200K cluster where the preclinical OM testing was setting up



# **Study Plan: First Part**



# **Study Plan: Second Part**



# State of Art

- 72 subjects enrolled: 30 Male and 42 Female
- Mean age: 51.2 (range 19-90)
- All undewent to OM brushing (except two) and blood withdrawal
- No complications were observed and all OM samples were suitable for the test
- Genetic analysis: 21 carriers of E200K mutation

### End Point Dilution of OM from patients with E200K PRNP mutation (Hamster PrP 23-231 at 42°C)



Time (h)



### RT-QuIC testing of OM using «Improved» RT-QuIC Conditions (Hamster PrP 90-231 at 55°C)



### RT-QuIC testing of OM using «Improved» RT-QuIC Conditions (Hamster PrP 23-231 at 55°C)



### RT-QuIC testing of OM using «Improved» RT-QuIC Conditions (Vole PrP 90-231 109M at 55°C)



# Summary

- Nasal brushing procedure was well tolerated by all subjects;
- The end-point dilution of OM from patients with E200K, using RT-QuIC standard conditions (Hamster PrP 23-231 at 42°C), was 10<sup>-6</sup>. No positive sample in OM from healthy family members;
- We tested different «Improved» RT-QuIC experimental conditions, changing PrP substrates of reaction and temperatures, for increasing the sensitivity without compromising the specificity of the test;
- We determined that the most appropriate «Improved condition» was Hamster PrP 23-231 at 55°C (OM resulted positive after 5 hours in E200K patient without false positive in other neurodegenerative disorders).